This article was originally published in Start Up
SIDDCO is not your traditional drug discovery start-up, eking out an existence by trying to create partnerships around a single technology. SIDDCO has three specialty technologies--combinatorial chemistry, high-density miniaturized screening and multi-array plate screening--to serve its string of corporate partners.
You may also be interested in...
Companies in the new generation of screening technologies are stressing content as much as they're stressing speed, and one-stop shopping as much as focused expertise.
As an industry, women's health is in its infancy. It has yet to develop beyond a collection of niche specialties in reproductive medicine and breast cancer.
EPIcyte has licensed patents from the Scripps Research Institute covering new methods of human antibody production in plants that can lower costs up to 100 fold. The company is also developing proprietary products based on its technology, initially, an anti-herpes prophylactic and a contraceptive based on an anti-sperm antibody.